The 5 most recent market catalysts affecting $SLDB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 65
RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18
RBC Capital's initiation of coverage on Solid Biosciences with an Outperform rating and an $18 price target is a significant event for the company. Analyst coverage, especially wit…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26
Cantor Fitzgerald analyst Kristen Kluska has maintained an 'Overweight' rating on Solid Biosciences (SLDB) and significantly raised the price target from $16 to $26. This action in…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on Solid Biosciences (SLDB) and raised the price target from $16 to $20. This analyst action signals increased co…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Solid Biosciences Files Prospectus To Offer Up To $200M In Common Stock
Solid Biosciences filed a prospectus to offer up to $200 million in common stock. This action signals the company's intent to raise capital, likely to fund its ongoing research and…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Solid Biosciences Files Prospectus For Mixed Shelf Offering; Size Not Disclosed
Solid Biosciences has filed a mixed shelf offering prospectus, which is a common corporate finance tool that allows a company to register various types of securities (e.g., common …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.